Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > New Topical Therapy Safely Treats Serious Skin Infections

Abstract:
A new topical lotion that penetrates the skin deeply enough to target and eliminate serious skin infections, but without being systemically absorbed, has shown a high degree of safety and tolerability in patients with onychomycosis, or toenail fungus, a new study has shown.

New Topical Therapy Safely Treats Serious Skin Infections

Ann Arbor, MI | Posted on September 19th, 2007

"Results of the phase 1 clinical trial are important to the fields of dermatology and infectious diseases because currently approved systemic medications for onychomycosis carry serious risks of cardiac and liver toxicity," said James Baker, MD, chief science officer and founder of NanoBio Corporation in Ann Arbor, Mich.

The phase 1 data for the new lotion, NB-002, will be presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting, to be held Sept. 17 -20, 2007, in Chicago.

"At present, the vast majority of people with onychomycosis are untreated as a result of concerns for the serious toxicities associated with the available oral medications," said Baker, whose team developed the lotion. "Our safety data, combined with early information from the ongoing phase 2 trial, indicate that NB-002 is potentially the first treatment for onychomycosis that is highly efficacious and very safe."

NanoBio Corporation is a spin-off from the University of Michigan. The company develops novel anti-infective products and mucosal vaccines to treat or prevent a wide range of infections, from cold sores and toenail fungus to influenza and hepatitis B. Its lead products are NB-001 to treat herpes labialis and NB-002 to treat onychomycosis.

NB-002 is a topical oil-in-water nanoemulsion combined with an antimicrobial agent commonly used in oral products to treat gingivitis and other conditions of the mouth and throat. The nanoemulsion undergoes a high-energy process to shrink or "nano-size" the particles so they are small enough to enter the skin through pores and hair follicles but too large to penetrate the tight junctions of the epithelium.

As a result, NB-002 is not systemically absorbed, as the phase 1 study has demonstrated. In the study, 20 subjects with advanced onychomycosis were randomized to receive two strengths of NB-002. Treatments were applied twice daily for 28 days to both affected and unaffected toenails and a small area of surrounding skin. Blood samples were collected periodically to determine if the drug was absorbed systemically.

Results showed the drug was below the quantifiable limit of systemic absorption for all subjects throughout the study period. Additionally, the trial showed that, unlike the current treatments for onychomycosis, NB-002 had no safety or dermal irritation concerns.

Results of a phase 2 clinical trial for onychomycosis are expected in early 2008.

In addition to its topical agents, NanoBio is developing a rich pipeline of needle-free vaccines based on using the same oil-in-water emulsion technology as an adjuvant. Mucosal vaccines against influenza and hepatitis are scheduled for human testing beginning next year, while an anthrax vaccine has demonstrated safety and strong efficacy in animal studies.

####

About NanoBio Corporation
NanoBio® Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), methicillin-resistant Staphylococcus aureus (MRSA) and mucosal vaccines for influenza and hepatitis B. The company’s headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

Contacts:
NanoBio® Corporation
2311 Green Road, Suite A
Ann Arbor, Michigan 48105
734.302.4000
734.302.9150

Copyright © NanoBio Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project